Metronomic chemotherapy: New rationale for new directions

Nature Reviews Clinical Oncology

Volumn 7, Issue 8, 2010, Pages 455-465

  Pasquier, Eddy ^a   Kavallaris, Maria ^a   André, Nicolas ^b  

^a University of New South Wales   (Australia)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DALTEPARIN; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LETROZOLE; METHOTREXATE; MINOCYCLINE; NAVELBINE; OCTREOTIDE; PACLITAXEL; PREDNISONE; RETINOIC ACID; ROFECOXIB; SORAFENIB; TEMOZOLOMIDE; THALIDOMIDE; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ADAPTIVE IMMUNITY; ANEMIA; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FATIGUE; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY CARCINOMA; LEUKEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; METRONOMIC CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955172181     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.82     Document Type: Review

References (119)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
3. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
4. Bergers, G. and Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
5. Jain, R. K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
6. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
7. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
8. Loges, S., Mazzone, M., Hohensinner, P, and Carmeliet, P Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167-170 (2009).
9. Kerbel, R. S. and Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4, 423-436 (2004).
10. Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2, 733-740 (2001).
11. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31-36 (1991).
12. Klement, G. et al. Continuous low-dose therapy with vinblastine and vEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
13. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
14. Hanahan, D., Bergers, G. and Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
15. Sarmiento, R. and Gasparini, G. Antiangiogenic metronomic chemotherapy. Onkologie 31, 161-162 (2008).
16. Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73-80 (2002).
17. Colleoni, M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17, 232-238 (2006).
18. Wong, N. S. et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28, 723-730 (2010).
19. Gonzalez-Billalabeitia, E. et al. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. Breast J. 15, 551-553 (2009).
20. Bottini, A. et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 24, 3623-3628 (2006).
21. Orlando, L. et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6, 225 (2006).
22. Dellapasqua, S. et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26, 4899-4905 (2008).
23. Garcia-Saenz, J. A. et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer. J. Chemother. 20, 632-639 (2008).
24. Jurado Garcia, J. M. et al. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin. Transl. Oncol. 10, 583-586 (2008).
25. Garcia, A. A. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26, 76-82 (2008).
26. Glode, L. M., Barqawi, A., Crighton, F., Crawford, E. D. and Kerbel, R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98, 1643-1648 (2003).
27. Nicolini, A. et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 58, 447-450 (2004).
28. Lord, R. et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J. Urol. 177, 2136-2140 (2007).
29. Fontana, A. et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin. Cancer Res. 15, 4954-4962 (2009).
30. de Weerdt, O. et al. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth. J. Med. 59, 50-56 (2001).
31. Buckstein, R. et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin. Cancer Res. 12, 5190-5198 (2006).
32. Kong, D. S. et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol. Rep. 16, 1117-1121 (2006).
33. Perry, J. R., Rizek, P, Cashman, R., Morrison, M. and Morrison, T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 113, 2152-2157 (2008).
34. Reardon, D. A. et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br. J. Cancer 101, 1986-1994 (2009).
35. Brizzi, M. P et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9, 388 (2009).
36. Young, S. D. et al. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin. Cancer Res. 12, 3092-3098 (2006).
37. Steinbild, S. et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase II study. Onkologie 30, 629-635 (2007).
38. Kesari, S. et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro. Oncol. 9, 354-363 (2007).
39. Krzyzanowska, M. K. et al. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother. Pharmacol. 60, 135-141 (2007).
40. Sterba, J. et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29, 308-313 (2006).
41. Kieran, M. W. et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol. 27, 573-581 (2005).
42. du Manoir, J. M. et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin. Cancer Res. 12, 904-916 (2006).
43. Watanabe, T. et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J. Clin. Oncol. 27, 1368-1374 (2009).
44. Briasoulis, E. et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 15, 6454-6461 (2009).
45. Nannini, M. et al. To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother. Pharmacol. 64, 189-193 (2009).
46. Spieth, K., Kaufmann, R. and Gille, J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother. Pharmacol. 52, 377-382 (2003).
47. Borne, E. et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest. New Drugs doi:10.1007/ s10637-009-9298-9305
48. Vogt, T. et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98, 2251-2256 (2003).
49. Reichle, A. and Vogt, T. Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron. 1, 159-170 (2008).
50. Kato, H. et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713-1721 (2004).
51. Herrlinger, U. et al. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J. Neurooncol. 71, 295-299 (2005).
52. Bhatt, R. S. et al. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116, 1751-1756 (2010).
53. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
54. Yagoda, A., Abi-Rached, B. and Petrylak, D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22, 42-60 (1995).
55. Bellmunt, J. et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 11, 350-357 (2010).
56. Sterba, J., Pavelka, Z. and Slampa, P Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49, 117-120 (2002).
57. Choi, L. M. et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr. Blood Cancer 50, 970-975 (2008).
58. Stempak, D. et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J. Pediatr. Hematol. Oncol. 28, 720-728 (2006).
59. Andre, N. et al. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin. Ther. 30, 1336-1340 (2008).
60. Le Deley, M. C. et al. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr. Blood Cancer 45, 25-31 (2005).
61. De Vita, S. et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann. Hematol. 84, 760-762 (2005).
62. Rome, A. et al. Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis. Pediatr. Blood Cancer 53, 246-247 (2009).
63. Bocci, G., Nicolaou, K. C. and Kerbel, R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943 (2002).
64. Miller, K. D., Sweeney, C. J. and Sledge, G. W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206 (2001).
65. Pasquier, E., Andre, N. and Braguer, D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr. Cancer Drug Targets 7, 566-581 (2007).
66. Laquente, B., Vinals, F. and Germa, J. R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 9, 93-98 (2007).
67. Dunn, G. P, Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
68. Zitvogel, L., Apetoh, L., Ghiringhelli, F and Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008).
69. Kosmaczewska, A., Ciszak, L., Potoczek, S. and Frydecka, I. The significance of Treg cells in defective tumor immunity. Arch. Immunol. Ther. Exp. (Warsz) 56, 181-191 (2008).
70. Kono, K. et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55, 1064-1071 (2006).
71. Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344 (2004).
72. Loeffler, M., Kruger, J. A. and Reisfeld, R. A. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res. 65, 5027-5030 (2005).
73. Lutsiak, M. E. et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868 (2005).
74. Banissi, C., Ghiringhelli, F., Chen, L. and Carpentier, A. F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58, 1627-1634 (2009).
75. Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007).
76. Generali, D. et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin. Cancer Res. 15, 1046-1051 (2009).
77. Tanaka, H., Matsushima, H., Mizumoto, N. and Takashima, A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 69, 6978-6986 (2009).
78. Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E. and Takashima, A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 69, 6987-6994 (2009).
79. Man, S. et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731-2735 (2002).
80. Klement, G. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8, 221-232 (2002).
81. Huang, J. et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2, 36-42 (2004).
82. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007).
83. Udagawa, T. Tumor dormancy of primary and secondary cancers. APMIS 116, 615-628 (2008).
84. Bergers, G. and Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410 (2003).
85. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004).
86. Gimbrone, M. A. Jr, Leapman, S. B., Cotran, R. S. and Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276 (1972).
87. Brem, S., Brem, H., Folkman, J., Finkelstein, D. and Patz, A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36, 2807-2812 (1976).
88. Finkelstein, D. et al. Experimental retinal neovascularization induced by intravitreal tumors. Am. J. Ophthalmol. 83, 660-664 (1977).
89. Matsuzawa, A., Takeda, Y., Narita, M. and Ozawa, H. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811). Int. J. Cancer 49, 303-309 (1991).
90. Schirrmacher, V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin. Cancer Biol. 11, 285-295 (2001).
91. Mahnke, Y. D., Schwendemann, J., Beckhove, P and Schirrmacher, V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115, 325-336 (2005).
92. Andre, N. and Pasquier, E. Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat. Clin. Pract. Oncol. 6, E1 (2009).
93. Seruga, B. and Tannock, I. F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 5, 574-576 (2008).
94. Chuu, C. P, Hiipakka, R. A., Fukuchi, J., Kokontis, J. M. and Liao, S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 65, 2082-2084 (2005).
95. Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A. and Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68, 4518-4524 (2008).
96. Cabral, F. R. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J. Cell Biol. 97, 22-29 (1983).
97. Schibler, M. J. and Cabral, F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha-and beta-tubulin. J. Cell Biol. 102, 1522-1531 (1986).
98. Kavallaris, M. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100, 1282-1293 (1997).
99. Yang, C. P et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol. Cancer Ther. 4, 987-995 (2005).
100. Gatenby, R. A., Silva, A. S., Gillies, R. J. and Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894-4903 (2009).
101. Mancuso, P et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459 (2006).
102. Bertolini, F., Mancuso, P, Shaked, Y. and Kerbel, R. S. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today 12, 806-812 (2007).
103. Bertolini, F., Mancuso, P, Braidotti, P, Shaked, Y. and Kerbel, R. S. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochim. Biophys. Acta 1796, 27-32 (2009).
104. Hida, A. et al. Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis. J. Lab. Clin. Med. 144, 148-155 (2004).
105. Rigolin, G. M. et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107, 2531-2535 (2006).
106. Hida, K., Hida, Y. and Shindoh, M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci. 99, 459-466 (2008).
107. Streubel, B. et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351, 250-259 (2004).
108. Xiong, Y. Q. et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 15, 4838-4846 (2009).
109. Virrey, J. J. et al. Glioma-associated endothelial cells are chemoresistant to temozolomide. J. Neurooncol. 95, 13-22 (2009).
110. Ohtani, N., Mann, D. J. and Hara, E. Cellular senescence: Its role in tumor suppression and aging. Cancer Sci. 100, 792-797 (2009).
111. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715 (2003).
112. Zetterberg, A. and Larsson, O. Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc. Natl Acad. Sci. USA 82, 5365-5369 (1985).
113. Coller, H. A., Sang, L. and Roberts, J. M. A new description of cellular quiescence. PLoS Biol. 4, e83 (2006).
114. Goymer, P Natural selection: The evolution of cancer. Nature 454, 1046-1048 (2008).
115. Meiler, J. and Schuler, M. Therapeutic targeting of apoptotic pathways in cancer. Curr. Drug Targets 7, 1361-1369 (2006).
116. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13, 1859-1876 (2006).
117. Merlo, L. M., Pepper, J. W., Reid, B. J. and Maley, C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935 (2006).
118. Andre, N. and Pasquier, E. For cancer, seek and destroy or live and let live? Nature 460, 324 (2009).
119. Marusyk, A. and Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 1805, 105-117 (2010).